Endothelial cells are a vital constituent of most mammalian organs and are required to maintain the integrity of these tissues. These cells also play a major role in angiogenesis, inflammatory reactions, and in the regulation of thrombosis. Angiogenesis facilitates pulp formation and produces the vessels which are essential for the maintenance of tooth homeostasis. These vessels can also be used in bone and tissue regeneration, and in surgical procedures to place implants or to remove cancerous tissue. Furthermore, endothelial cell regeneration is the most critical component of the tooth generation process. The aim of the present study was to stimulate endothelial regeneration at a site of acute cyclophosphamide (CP)-induced endothelial injury by treatment with human umbilical cord-derived endothelial/mesenchymal stem cells (hEPCs). We randomly assigned 16 to 20-week-old female NOD/SCID mice into three separate groups, a hEPC (1 × 105 cells) transplanted, 300mg/kg CP treated and saline (control) group. The mice were sacrificed on days 5 and 10 and blood was collected via the abdominal aorta for analysis. The alanine transaminase (ALT), aspartate aminotransferase (AST), serum alkaline phosphatase (s-ALP), and albumin (ALB) levels were then evaluated. Tissue sections from the livers and kidneys were stained with hematoxylin and eosin (HE) for microscopic analysis and were subjected to immunohistochemistry to evaluate any changes in the endothelial layer. CP treatment caused a weight reduction after one day. The kidney/body weight ratio increased in the hEPC treated animals compared with the CP only group at 10 days. Moreover, hEPC treatment resulted in reduced s-ALP, AST, ALT levels compared with the CP only group at 10 days. The CP only animals further showed endothelial injuries at five days which were recovered by hEPC treatment at 10 days. The number of CD31-positive cells was increased by hEPC treatment at both 5 and 10 days. In conclusion, the CP-induced disruption of endothelial cells is recovered by hEPC treatment, indicating that hEPC transplantation has potential benefits in the treatment of endothelial damage.

Recovery 01' original form ancl function from c1amaged organs 01' tissues is olltmost goal of regenera tive meclicine. Va riolls methods such as moleclll ar biology. drug c1elivery system, biomaterials. tissue engineering have been s tllcliecl and appl iecl in that field . 1'he core factor of all 01' these kinds of efforts might be the cells including stem cells 01' progenitor cell s . AclllJt progenitor 01' stem cells have many advantages for therapeutic meclicine, inclucling free form ethi cal probl em. easiness in collection and clllture. Bone marrow‘ fat tissue, peripheral blood. placenta‘ ancl umbilicaJ cord bloocl a re preferable source 01' acllllt stem cells 01' progenitors. ]-]uman umbilical cord bloocl. taken form vein of corcl after baby c1elivery‘ are known to contain many progenitor cells. Since Boyse et al reportecl bone marrow transplantation with hllman cord blood CD34+ cells f'or leukemia. functional cells in human cord blood have been the cells of great interest. 1n this study‘ the a u thors i s이 ated peripheral bloocl mononuciear celJs. endothelial progenitors‘ late outgrowth vascular endothelial-like cells‘ ancl mesenchymal stem cell- like cells from human umbilical cord blood and a pplied in bony defects, myocardiac infarction and limb ischemic lesl0n Al I of these fllnctional cells showed favorable healing capacity and their effects primarily based on enhanced anglOgenesls Conclllsively. a lthollgb the precise cha racteristics are not well-described‘ the current stucly reveals that various types of functional cell s of human umbilical cord blood have some stem cell or progenitors features and play an important r ole in ti ssue regeneration

3BK21 program for Veterinary Science, College of Veterinary Medicine‘ Seoul National University. Seoul. Korea Human Co1'd blood has been used for the alternatives of bone marrow transplantation for more 10 years. Recently Mesenchymal s tem cell s , ES-like cells and endothelial stem cells has been successfuly isolated from huam co1'd blood Presentl y. it has been reported that a bout 70 incurable ans tractible di sease was possibly cured by umbili cal cord blood-deri ved s tem cells in the clinit;al test s‘ However‘ isolation and expansion of s tem cells from human umbilical cord blood(UCB) have been very difficult and an obstrucle for the clinical use This study showed that effi cient s iolat iona and expans ion of mesenchymal stem cells from UCB Full term UCB samples were obtained from the umbi lical vein after vaginal deli ve ry with the informed consent 0 1' the mothe1' approved by Borame Hospital Institutional Review Broad (IRB). And a lso. t his work was also a pproved by Seoul National University IRB. Recently, we isolated a population of s tem cells from human corcl bloocl (UCB)‘ which expressed embryo stage specific maker. SSEA-4. ancl the multi-potential stem cell marker‘ 。c t4 And we have sucessfully developed culture methods to expand ancl subculture these cells up to 1.000 billion from one single clone. Subsequently. we were a ble to transclifferente theses stem cells into insulin- producing is let- like structures. which co-express in sulin andC-pepticle, adipocyte, neuron‘ bone and cartilage. In acldition. the isola tion rate of MSC from UCB is about 70 % from the cord blood units. This isolation rate were not affected by maternal ages. the sex of baby, isolation time from the deli very. for example. 12 hrs. 24 hrs ‘ even 48 hrs from delivery Taken together. these findings might have a s ignificant potential to aclvance human UCB clerivecl stem- cell -basecl ther apeutics fOI' clinical use in near future

인간 제대혈 세포는 조혈모세포, 중간엽 줄기세포와내피전구세포를 풍부하게 포함하고 있다. 인간 제대혈 속의 중간엽 줄기세포는 조혈모세포와는 달리 다능성 줄기세포이며 신경세포로 분화할 수 있는 잠재성을 가지고 있다. 본 연구에서는 세포배양을 통해 제대혈의 중간엽 줄기세포를 신경세포와 콜린성 신경세포로 분화를 유도하였다. 중간엽 줄기세포를 신경세포로 분화시키기 위해 배양액에 dimethyl sulphoxide(DMSO)와 butylated hydroxyani

Human umbilical cord blood cells(HUCBC) are rich in mesenchymal progenitor cells, endothelial cell precursors and hematopoietic cells. HUCBC have been used as a source of transplantable stem and progenitor cells. However, little is known about survival and development of HUCBC transplantation in the CNS. Estrogen has a neuroprotective potential against oxidative stress-induced cell death so has an effect on reducing infarct size of ischemic brain. We investigated the potential use of HUCBC as donor cells and tested whether estrogen mediates intravenously infused HUCBC enter and survive in ischemic brain. PKH26 labeled mononuclear fraction of HUCBC were injected into the tail vein of ischemic OVX rat brain with or without -estradiol valerate(EV). Under fluorescence microscopy, labeled cells were observed in the brain section. Significantly more cells were found in the ischemic brain than in the non-ischemic brain. HUCBC transplanted into ischemic brain could migrate and survive. Some of cells have shown neuronal like cells in hippocampus, striatum and cortex tissues. These result suggest that estrogen reduces ischemic damage and increases the migration of human umbilical cord blood cells. This Study was supported by the Korea Science and Engineering Foundation(KOSEF) though the Biohealth Products Research Center(BPRC), Inje University, Korea.